Method for Inducing T-Cell Proliferation

Description:
This technology relates to the use of thymic stromal lymphopoietin (TSLP) to induce CD4+ T cell proliferation. This proliferation could be of particular relevance for patients in whom this cell population has been significantly reduced by HIV/AIDS or other conditions resulting in immunodeficiency. The proliferation of isolated CD4+ T cells can be induced through direct contact with TSLP or a nucleic acid encoding TSLP. The patent application also describes methods of inducing or enhancing an immune response through administration of CD4+ T cells that have been isolated and induced to proliferate using TSLP or a nucleic acid encoding TSLP. TSLPR knockout mice are also described in the patent application and available for licensing through a biological materials license agreement.
Patent Information:
For Information, Contact:
Vincent Kolesnitchenko
Technology Development Specialist
NIH Technology Transfer
301-594-4115
vk5q@nih.gov
Inventors:
Warren Leonard
Keywords:
DBXXXX
DXXXXX
Hyper IgM syndrome
Immunodeficiency 2
Immunodeficiency 4
Immunodeficiency-3
Severe combined immunodeficiency, x-linked
Wiskott Aldrich syndrome
© 2024. All Rights Reserved. Powered by Inteum